For the study of aluminium levels in renal failure patients on hemodialysis, 40 patients and 40 normal healthy individuals were selected. Blood urea and serum creatinine were determined in order to differentiate between normals and patients. In patients, the values of these two parameters were consistently higher than those in the normals. Statistical analysis also revealed significantly higher levels of aluminum in patients as compared to the normal individuals. Average serum Al+3 level in renal patients was 150 µ g/L, much higher than the toxic Al+3 level (100 µ g/L). In view of frequent use of aluminum containing preparation to combat hyper phosphatemia in chronic renal failure patients the management of hyperaluminemia complication become indispensable. Therefore, useful information obtained from experimental study could be judiciously implemented by the clinicians in perspective of ongoing therapeutic management of such patients. So, clinicians must avoid prescribing aluminium preparations to patients with chronic renal failure over longer period. The suggestive alternative for reducing aluminium toxicity is to use non-aluminium compounds for hemodialysis.